| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
04-02-2017, 03:20 PM
|
#1 | ||
|
|||
|
News Gatherer
Community Support Team
|
Endpoints News Roche, Prothena hustle to PhII with their disease-modifying Parkinson's drug targeting alpha-synuclein Endpoints News Prothena turned up at the big Alzheimer's/Parkinson's conference in Vienna over the weekend to detail early-stage data showing how its Roche-partnered drug PRX002/RG7935 can flush out toxic clusters of alpha-synuclein in Parkinson's patients. And they ... Clinical Results Presented from Prothena's Phase 1b Study of PRX002/RG7935 Demonstrating Robust Antibody CNS ...Yahoo Finance all 2 news articles » More... |
||
|
 Reply With Quote
|
| Reply |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| Disease-modifying strategies for Parkinson's disease | Parkinson's Disease | |||
| Prothena rockets up with early data on a Roche-partnered Parkinson's drug | Parkinson's Disease | |||
| Roche to Award $30M Milestone for Prothena's Parkinson's Drug | Parkinson's Disease | |||
| Disease-modifying drugs for Parkinson's predicted within 10 years | Parkinson's Disease | |||
| Roche and reMynd Partner to Develop Disease-Modifying AD and PD Candidates | Parkinson's Disease | |||
Roche, Prothena hustle to PhII with their disease-modifying Parkinson's drug targetin
Linear Mode
